{
    "title": "112_s1734",
    "content": "The Act titled \"Generating Antibiotic Incentives Now Act of 2011\" includes provisions for extending exclusivity periods for drugs, priority review, fast track products, and incentives for infectious disease biological products. It also addresses clinical trials and companion diagnostic tests. SEC. 505E. Extension of exclusivity period for new qualified infectious disease products. Extension of exclusivity period for new qualified infectious disease products allows for a five-year extension if the drug is determined to be qualified. This extension is in addition to any pediatric exclusivity extensions. The extension of exclusivity period for qualified infectious disease products allows for a five-year extension for certain changes or modifications to the product that do not affect safety or effectiveness. The manufacturer or sponsor of a drug may request the Secretary to designate a drug as a qualified infectious disease product, with the Secretary determining this designation within 30 days. Regulations for this process must be established within 12 months of the enactment of this section. A qualified infectious disease product is an antibiotic drug used to treat, detect, prevent, or identify specific pathogens, including resistant gram positive and gram negative bacteria, multi-drug resistant tuberculosis, and other infectious pathogens designated by the Secretary. Section 505E of the Federal Food, Drug, and Cosmetic Act applies to drugs first approved under section 505(c) on or after the enactment of this Act. SEC. 4. ADDITIONAL EXTENSION OF EXCLUSIVITY PERIOD FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS WITH COMPANION DIAGNOSTIC TESTS CLEARED OR APPROVED. The Act is further amended to include an additional extension of exclusivity for these products. The Act is amended to provide a 6-month extension of exclusivity for qualified infectious disease products with companion diagnostic tests identified before the original exclusivity period expires. Identification of the companion diagnostic test must occur before the initial exclusivity period ends. The device must be determined by the Secretary to be a companion diagnostic test for the qualified infectious disease product. The Act is amended to provide a 6-month extension of exclusivity for qualified infectious disease products with companion diagnostic tests identified before the original exclusivity period expires. The device must be determined by the Secretary to be a test for diagnosis of a qualifying pathogen and cleared or approved. The sponsor of the product has exclusive rights to submit an identification with respect to the device. This extension is in addition to any extension under Pediatric Exclusivity. The Act allows for a 6-month extension of exclusivity for qualified infectious disease products with companion diagnostic tests identified before the original exclusivity period expires. The sponsor can request the Secretary to determine if a device is a test for diagnosis of a qualifying pathogen, with limitations on subsequent extensions for the same product or other products. The Act allows for a 6-month extension of exclusivity for qualified infectious disease products with companion diagnostic tests. Sponsors can request the Secretary to determine if a device is a test for diagnosis of a qualifying pathogen. SEC. 524A. PRIORITY REVIEW FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS. Priority review is given to qualified infectious disease products by the Secretary under section 505E(c). This means that any application for approval of such drugs under section 505(b) will be reviewed and acted upon within 6 months. This provision applies to applications submitted after the enactment of the Act. SEC. 6 amends the Federal Food, Drug, and Cosmetic Act to include drugs intended for serious conditions or qualified infectious disease products. SEC. 7 involves a study on incentives for qualified infectious disease biological products. The Comptroller General of the United States will conduct a study on incentives for infectious disease biological products and submit a report to Congress within a year. Definitions for biological products and qualified infectious disease biological products are provided. The Comptroller General of the United States will conduct a study on incentives for infectious disease biological products and submit a report to Congress within a year. The term \"qualifying pathogen\" is defined in section 505E of the Federal Food, Drug, and Cosmetic Act. SEC. 8. CLINICAL TRIALS. The Secretary must review and revise FDA guidelines for clinical trials of antibiotic drugs within specified timeframes to incorporate advancements in scientific and medical knowledge and ensure clarity on approval procedures under the Federal Food, Drug, and Cosmetic Act. The Secretary must review and revise FDA guidelines for clinical trials of antibiotic drugs within specified timeframes to incorporate advancements in scientific and medical knowledge and ensure clarity on approval procedures under the Federal Food, Drug, and Cosmetic Act. Paragraph (1) addresses appropriate animal models of infection, in vitro techniques, valid micro-biological surrogate markers, use of non-inferiority versus superiority trials, and appropriate delta values for non-inferiority trials. Rule of construction states that nothing in this section shall repeal or affect FDA guidelines. Recommendations for Investigations allow sponsors to request written recommendations for nonclinical and clinical investigations for drugs intended to treat qualifying pathogens. The Secretary provides recommendations for nonclinical and clinical investigations needed for drug approval under section 505 of the Federal Food, Drug, and Cosmetic Act. In this section, definitions for the terms \"drug,\" \"qualifying pathogen,\" and \"Secretary\" are provided as per the Federal Food, Drug, and Cosmetic Act."
}